Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Esperion Therapeutics Inc’s stock clocked out at $1.59, down -3.64% from its previous closing price of $1.65. In other words, the price has decreased by -$3.64 from its previous closing price. On the day, 3.51 million shares were traded.
Ratios:
To gain a deeper understanding of ESPR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.37 and its Current Ratio is at 1.85.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on December 18, 2024, initiated with a Neutral rating and assigned the stock a target price of $4.
On December 17, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $8.
BofA Securities Downgraded its Neutral to Underperform on June 20, 2024, while the target price for the stock was maintained at $2.50.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 19 ’25 when Warren Eric sold 239 shares for $1.87 per share. The transaction valued at 446 led to the insider holds 159,759 shares of the business.
Halladay Benjamin sold 11 shares of ESPR for $20 on Feb 19 ’25. The Chief Financial Officer now owns 240,671 shares after completing the transaction at $1.86 per share. On Feb 19 ’25, another insider, Warren Eric, who serves as the Officer of the company, bought 239 shares for $1.87 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.06.
Stock Price History:
Over the past 52 weeks, ESPR has reached a high of $3.94, while it has fallen to a 52-week low of $1.57. The 50-Day Moving Average of the stock is -19.86%, while the 200-Day Moving Average is calculated to be -26.48%.
Shares Statistics:
A total of 195.44M shares are outstanding, with a floating share count of 195.08M. Insiders hold about 0.99% of the company’s shares, while institutions hold 66.15% stake in the company.
Earnings Estimates
The current rating of Esperion Therapeutics Inc (ESPR) is the result of assessments by 3.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.12 and low estimates of -$0.18.
Analysts are recommending an EPS of between $0.05 and -$0.1 for the fiscal current year, implying an average EPS of -$0.03. EPS for the following year is -$0.22, with 1.0 analysts recommending between -$0.22 and -$0.22.
Revenue Estimates
In the current quarter, 6 analysts expect revenue to total $54.97M. It ranges from a high estimate of $63.8M to a low estimate of $44.4M. As of the current estimate, Esperion Therapeutics Inc’s year-ago sales were $137.74MFor the next quarter, 6 analysts are estimating revenue of $61.74M. There is a high estimate of $69.8M for the next quarter, whereas the lowest estimate is $50.73M.
A total of 9 analysts have provided revenue estimates for ESPR’s current fiscal year. The highest revenue estimate was $420.5M, while the lowest revenue estimate was $320.02M, resulting in an average revenue estimate of $348.5M. In the same quarter a year ago, actual revenue was $332.31MBased on 6 analysts’ estimates, the company’s revenue will be $345.01M in the next fiscal year. The high estimate is $430.12M and the low estimate is $274.2M.
